A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Clinical trial NCT06241118 · RECRUITING
Trial details
- NCT number
- NCT06241118
- Sponsor
- Sanofi
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-29
- Primary completion
- 2027-09-30
- Enrollment
- 636
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.